Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8101 to 8115 of 9128 results

  1. Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]

    In development Reference number: GID-TA11336 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Optical Coherence Tomography to guide percutaneous coronary intervention

    In development Reference number: GID-HTG10884 Expected publication date: TBC

    HealthTech guidance
    In development

  3. Peezy Midstream for urine collection (MT446)

    In development Reference number: GID-HTG10892 Expected publication date: TBC

    HealthTech guidance
    In development

  4. Zio XT for detecting cardiac arrhythmias

    In development Reference number: GID-HTG10895 Expected publication date: TBC

    HealthTech guidance
    In development

  5. Surgical vessel sealing systems (MT798)

    Discontinued Reference number: GID-HTG10894

    HealthTech guidance
    Discontinued

  6. GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain

    Discontinued Reference number: GID-HTG10896

    HealthTech guidance
    Discontinued

  7. Non-invasive skin closure devices for surgical incisions (MT775)

    Discontinued Reference number: GID-HTG10897

    HealthTech guidance
    Discontinued

  8. Digital technologies to support smoking cessation in secondary care patients: early value assessment

    In development Reference number: GID-HTG10889 Expected publication date: TBC

    HealthTech guidance
    In development

  9. Vosoritide for treating achondroplasia in people 4 months and over [ID6488]

    In development Reference number: GID-TA11528 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Depemokimab for treating severe eosinophilic asthma in people 12 years and over [ID6447]

    In development Reference number: GID-TA11553 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Crovalimab for treating atypical haemolytic uraemic syndrome [GID-TA12006]

    In development Reference number: GID-TA12006 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6473]

    In development Reference number: GID-TA11582 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]

    Discontinued Reference number: GID-TA10334

    Technology appraisal guidance
    Discontinued

  14. Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer [ID1509]

    Discontinued Reference number: GID-TA10413

    Technology appraisal guidance
    Discontinued

  15. Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]

    Discontinued Reference number: GID-TA10151

    Technology appraisal guidance
    Discontinued